PDCD1 and neoplasm: When PD-1/PD-L1 inhibitors were compared with chemotherapy, the risk of peripheral neuropathy of all grades was noticeably lower [OR = 0.07, 95%CI:(0.04, 0.13), I2 = 62%, Z = 8.48 (P < 0.00001); Figure 3A1], even for every subgroup relating to different tumor types (24–26, 30–32, 34, 38, 40, 41, 43, 44, 46).